Analysis of Antibody Responses After COVID-19 Vaccination in Liver Transplant Recipients: A Single-Center Study

被引:2
作者
Oh, Young Ju [1 ]
Kim, Jongman [2 ,4 ]
Kang, Eun-Suk [3 ,5 ]
Rhu, Jinsoo [2 ]
Choi, Gyu-Seong [2 ]
Joh, Jae-Won [2 ]
机构
[1] Korea Univ, Anam Hosp, Sch Med, Dept Surg, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Surg, Seoul, South Korea
[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Lab Med & Genet, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, 81 Irwon Ro, Seoul, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Lab Med & Genet, 81 Irwon Ro, Seoul, South Korea
关键词
Young Ju Oh; COVID-19; Vaccination; Anti-SARS-CoV-2 S Antibody; Liver Transplantation; Tacrolimus;
D O I
10.3346/jkms.2023.38.e121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Liver transplant (LT) recipients were considered a vulnerable population during the coronavirus disease 2019 (COVID-19) pandemic. The clinical efficacy of the COVID-19 vaccine is unknown in immunocompromised patients. The purpose of this study was to provide evidence of antibody responses after COVID-19 vaccination in LT recipients.Methods: This study enrolled 46 patients who underwent LT at Samsung Medical Center (Seoul, Korea) before implementation of the one-dose vaccine in Korea. Those who completed the two-dose COVID-19 vaccine between August 2021 and September 2021 were included and followed through December 2021. Semiquantitative anti-spike serologic testing was performed using the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay (Roche Diagnostics, Rotkereuz, Switzerland) with a positive cutoff of at least 0.8 U/mL. Results: Among all 46 participants, 40 (87%) demonstrated an antibody response after the second dose of a COVID-19 vaccine, while six (13%) had no antibody response after the second dose. Upon univariate analysis, patients with higher antibody titer had longer years since LT (2.3 +/- 2.8 vs. 9.4 +/- 5.0, P < 0.001). A lower median tacrolimus (TAC) level before vaccination and after the second dose of COVID-19 vaccine indicated a significantly higher antibody response (2.3 [1.6-3.2] vs. 7.0 [3.7-7.8], P = 0.006, 2.5 [1.6-3.3] vs. 5.7 [4.2-7.2], P = 0.003). Period between 2nd vaccination and serologic testing was significantly higher in the antibody-response group compared to the no-antibody-response group (30.2 +/- 24.0 vs. 65.9 +/- 35.0, P = 0.012). A multivariate analysis of antibody responses revealed TAC level before vaccination as a statistically significant factor.Conclusion: A higher TAC level before vaccination resulted in less effective vaccination in LT patients. Booster vaccinations are required, especially for patients in the early stage after LT who have compromised immune function.
引用
收藏
页数:5
相关论文
共 10 条
[1]   Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [J].
Alejo, Jennifer L. ;
Mitchell, Jonathan ;
Chiang, Teresa P. -Y. ;
Abedon, Aura T. ;
Boyarsky, Brian J. ;
Avery, Robin K. ;
Tobian, Aaron A. R. ;
Levan, Macey L. ;
Massie, Allan B. ;
Garonzik-Wang, Jacqueline M. ;
Segev, Dorry L. ;
Werbel, William A. .
TRANSPLANTATION, 2021, 105 (12) :E280-E281
[2]   Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine [J].
Benotmane, Ilies ;
Gautier-Vargas, Gabriela ;
Cognard, Noelle ;
Olagne, Jerome ;
Heibel, FrancOise ;
Braun-Parvez, Laura ;
Martzloff, Jonas ;
Perrin, Peggy ;
Moulin, Bruno ;
Fafi-Kremer, Samira ;
Caillard, Sophie .
KIDNEY INTERNATIONAL, 2021, 99 (06) :1498-1500
[3]   Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients [J].
Boyarsky, Brian J. ;
Werbel, William A. ;
Avery, Robin K. ;
Tobian, Aaron A. R. ;
Massie, Allan B. ;
Segev, Dorry L. ;
Garonzik-Wang, Jacqueline M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (21) :2204-2206
[4]   Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients [J].
Boyarsky, Brian J. ;
Werbel, William A. ;
Avery, Robin K. ;
Tobian, Aaron A. R. ;
Massie, Allan B. ;
Segev, Dorry L. ;
Garonzik-Wang, Jacqueline M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (17) :1784-1786
[5]   COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis [J].
Cheung, Ka Shing ;
Mok, Chiu Hang ;
Mao, Xianhua ;
Zhang, Ruiqi ;
Hung, Ivan F. N. ;
Seto, Wai Kay ;
Yuen, Man Fung .
CLINICAL AND MOLECULAR HEPATOLOGY, 2022, 28 (04) :890-911
[6]   Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline [J].
Cho, Ju-Yeon ;
Lee, Young-Sun ;
Kim, Soon Sun ;
Song, Do Seon ;
Lee, Jeong-Hoon ;
Kim, Ji Hoon .
CLINICAL AND MOLECULAR HEPATOLOGY, 2021, 27 (04) :515-523
[7]   Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients [J].
Hall, Victoria G. ;
Ferreira, Victor H. ;
Ku, Terrance ;
Ierullo, Matthew ;
Majchrzak-Kita, Beata ;
Chaparro, Cecilia ;
Selzner, Nazia ;
Schiff, Jeffrey ;
McDonald, Michael ;
Tomlinson, George ;
Kulasingam, Vathany ;
Kumar, Deepali ;
Humar, Atul .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (13) :1244-1246
[8]   Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients [J].
Herrera, Sabina ;
Colmenero, Jordi ;
Pascal, Mariona ;
Escobedo, Miguel ;
Castel, Maria A. ;
Sole-Gonzalez, Eduard ;
Palou, Eduard ;
Egri, Natalia ;
Ruiz, Pablo ;
Mosquera, Mar ;
Moreno, Asuncion ;
Juan, Manel ;
Vilella, Anna ;
Soriano, Alex ;
Farrero, Marta ;
Bodro, Marta .
AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (12) :3971-3979
[9]  
Korea Centers for Disease Control and Prevention, DAILY REPORT MERS
[10]  
Ministry of Health and Welfare (KR), CORONAVIRUS COVID 19